EGFR wild-type

#ASCO23 Abs9025 #LCSM 🔬 SI-B001 + chemotherapy for locally advanced or metastatic EGFR/ALK wild-type NSCLC: Phase II study results 📋. ➡️ 55 patients enrolled, 48 evaluable for efficacy 💉. ➡️ ORR of 31.3% (15/48), DCR of 77.1% (37/48) 👏. ➡️ In Cohort B, Schedule 1, ORR was… https://t.co/DTfV3HzPHu (@ADesaiMD)

Includes resectable stage II/III (AJCC v8), EGFR/ALK wild type NSCLC. Pts receive 3 cycles of neoadjuvant chemotherapy + toripalimab vs placebo then surgery then 1 more cycle of adjuvant chemo (+tori/pbo) then 13 doses of maintenance toripalimab vs placebo. #ASCOPlenarySeries (@StephenVLiu)

STK11/LKB1 m are associated with poor prognosis particularly with IO in lung adeno, we found loss of LKB1 immunohistochemical protein expression in 66.3%, it was associated with short outcome in EGFRwt. @AndresFCardonaZ @diegoadiazg @RCatalanMD (@ogarrieta)

Patients with PDL1 high NSCLC (EGFR/ALK wild type) randomized to zimberelimab (PD-1) alone, zim + domvanalimab (TIGIT), or zim + dom + etrumadenant (A2R). Co-primary endpoints of RR and PFS. About 50 pts per arm. (@StephenVLiu)

First-Line Tremelimumab/Durvalumab/Chemotherapy May Become New Standard of Care in EGFR/ALK Wild-Type NSCLC #lungcancer #lcsm #oncology #nursing @MLJohnsonMD2 https://t.co/txav98AF82 (@OncNursingNews)

For PD-L1 positive and EGFR/ALK wild type NSCLC, it is highly possible that neoadjuvant IO is better than adjuvant IO. (@JoeChangMD)

SCI member @JoelNealMD et al. found that trastuzumab-based tx were not associated with > OS in patients with ERBB2-mutant, EGFR-wildtype #NSCLC. However, trastuzumab-based therapies were associated with > OS in patients with tumors with A775_G776insYVMA. https://t.co/ljHvYzUbkq (@SCIDirector)

And the evidence we have shows that patients with an EGFR mut+ NSCLC benefit at least as much from adjuvant chemo as pts w/EGFR wild type cancer, potentially more (@JackWestMD)

#ASCO22 Patritumab deruxtecan (HER3-DXd) in #EGFR wild type NSCLC from Dr. @ConorSteuerMD showed some efficacy - RR 29% and mPFS 10.8m in driver+ NSCLC and RR 27% and mPFS 4.2m - looking forward to confirmatory studies. (@StephenVLiu)

Patient with stage IIb (v7) NSCLC EGFRwt PD-L1 20% receives 3 cycles of chemo+nivo with partial pathologic response at lobectomy. Margins clear but they are cfDNA+ and want to do everything to maximize chance of cure. What would you do in adjuvant setting? (@PatelOncology)

I agree and wouldn't use the release to guide therapy. I think the topline reinforces the IMpower 010 results. I would stick to the published data and the approved agent in this setting: atezolizumab for PDL1+ (especially PDL1 high), EGFR/ALK wild type, stage II/III NSCLC. (@StephenVLiu)